PMA (premarket approval) review times continue to fall in the US
This article was originally published in Clinica
Executive Summary
The FDA has reduced further the time it takes to process applications to market medical devices in the US. In fiscal year 1998, which ended on September 31, the average review time for premarket approval applications (PMAs) from submission to approval fell to 12.4 months, a substantial 25% reduction on the 16.6 month average in 1997 and 50% less than the average of 25.9 months in 1996.
You may also be interested in...
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.
UK MHRA Updates Assistive Tech And Borderline Regulations
Device classification themes were uppermost in April for the UK regulator, which issued key guidance in two areas prone to complexities. It also contributed to the MedTech Directorate’s one-year progress report.